Mount Yale Investment Advisors LLC Increases Stake in Danaher Co. (NYSE:DHR)

Mount Yale Investment Advisors LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 43.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,641 shares of the conglomerate’s stock after acquiring an additional 805 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in Danaher were worth $660,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Frank Rimerman Advisors LLC raised its stake in Danaher by 638.3% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 16,457 shares of the conglomerate’s stock valued at $4,112,000 after purchasing an additional 14,228 shares during the period. ProShare Advisors LLC grew its position in Danaher by 7.9% in the second quarter. ProShare Advisors LLC now owns 96,531 shares of the conglomerate’s stock worth $24,118,000 after acquiring an additional 7,091 shares in the last quarter. Alaethes Wealth LLC increased its position in shares of Danaher by 3.1% during the 2nd quarter. Alaethes Wealth LLC now owns 6,960 shares of the conglomerate’s stock valued at $1,741,000 after purchasing an additional 206 shares during the last quarter. Legacy Financial Advisors Inc. boosted its position in shares of Danaher by 5.2% during the second quarter. Legacy Financial Advisors Inc. now owns 2,585 shares of the conglomerate’s stock valued at $646,000 after buying an additional 127 shares during the period. Finally, Summit Trail Advisors LLC boosted its holdings in Danaher by 3.1% during the 2nd quarter. Summit Trail Advisors LLC now owns 10,871 shares of the conglomerate’s stock valued at $2,719,000 after acquiring an additional 322 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.2 %

Danaher stock opened at $273.19 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a 50 day moving average price of $268.16 and a 200 day moving average price of $257.32. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a market capitalization of $202.35 billion, a PE ratio of 46.30, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm posted $2.05 earnings per share. The company’s revenue was down 2.9% on a year-over-year basis. Research analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio is presently 18.31%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on DHR shares. Robert W. Baird upped their target price on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. The Goldman Sachs Group boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Jefferies Financial Group started coverage on Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $278.94.

Insider Activity

In related news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.